Business Wire

Novotech Unveils 2024 Report on Global Gastric Cancer Clinical Trials and Cutting-Edge Therapeutics

4.9.2024 17:44:00 CEST | Business Wire | Press release

Share

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Gastric Cancer- Global Clinical Trial Landscape (2024).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903559744/en/

This report details the current gastric cancer (GC) research environment as it continues to evolve, as well as offering key insights into the trends that are expected to extend into the near future. The report examines the global state of clinical trials, drug discovery, and emerging therapeutic strategies, while also highlighting the significant progress in understanding and treating GC, showcasing promising therapeutic pipelines with potential benefits for patients and associated organizations worldwide.

The Novotech research analyst team provides these expert reports monthly, highlighting key metrics on the current status of specific diseases and outlining future trends that may impact the development of treatments. This is provided completely free of charge.

Key takeaways from the report:

  1. Global Clinical Trials Surge
    • Since 2019, over 2,000 clinical trials have been initiated globally, with the Asia-Pacific region leading the charge, accounting for 52% of all trials.
    • Mainland China, in particular, stands out with 48% of the region's trials, reflecting the region's commitment to advancing GC research.
    • North America and Europe also play crucial roles, contributing 29% and 15% of global trials, respectively.
  2. Innovative Drug Development
    • The report identifies 228 drugs in various stages of development, highlighting a robust pipeline aimed at improving GC treatment outcomes.
    • Notably, 11 drugs have already received approval, with 28 on the market, demonstrating the tangible progress made in recent years.
    • The most significant focus is on targeted therapies and immunotherapies, with nearly 40% of ongoing Phase III trials investigating Programmed Cell Death Protein 1 (PD-1) antagonists.
  3. Advanced Therapeutic Strategies
    • GC treatment strategies are increasingly shifting toward personalized medicine, with advancements in biomarker-directed therapies and molecular diagnostic techniques.
    • Perioperative chemotherapy remains the standard for resectable GC, while ongoing research explores the benefits of combining targeted and immunotherapies in both perioperative and adjuvant settings.
  4. GC Therapies Attract Significant Funding
    • From 2019 to 2023, GC research attracted substantial venture capital funding, totaling $7.4 billion globally.
    • China and the United States are the leading recipients, securing $4.53 billion and $2.97 billion, respectively.
    • This financial support underscores the global commitment to addressing the unmet needs of GC patients and advancing treatment options.
  5. Challenges and Opportunities
    • The report highlights ongoing challenges, including the high cost of advanced treatments and the need for better patient selection and tailored therapies.
    • However, significant opportunities exist in the form of liquid biopsies for detecting circulating DNA and the continued development of genetic and molecular profiling to personalize treatment approaches further.
  6. Market Leaders:
    • The report identifies key players in the GC treatment market, including Pfizer, Roche, Merck & Co., Eli Lilly and Co., and Sanofi
  7. Strategic Insights:
    • The report includes a SWOT analysis, demonstrating the effectiveness of current treatments in managing symptoms and improving quality of life, while also identifying areas where emerging techniques may offer improvements.

With ongoing clinical trials, innovative drug development, evolving therapeutic strategies, and continued investment of capital, the future of GC treatment looks promising.

For more information and to download the full report free of charge, please visit Novotech's website or contact our media relations team.

About NovotechNovotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903559744/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release

Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye